These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1130 related articles for article (PubMed ID: 33783147)

  • 1. COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology.
    Park JK; Lee EB; Shin K; Sung YK; Kim TH; Kwon SR; Lee MS; Hong SJ; Choi BY; Lee SS; Back HJ;
    J Korean Med Sci; 2021 Mar; 36(12):e95. PubMed ID: 33783147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
    Furer V; Eviatar T; Zisman D; Peleg H; Paran D; Levartovsky D; Zisapel M; Elalouf O; Kaufman I; Meidan R; Broyde A; Polachek A; Wollman J; Litinsky I; Meridor K; Nochomovitz H; Silberman A; Rosenberg D; Feld J; Haddad A; Gazzit T; Elias M; Higazi N; Kharouf F; Shefer G; Sharon O; Pel S; Nevo S; Elkayam O
    Ann Rheum Dis; 2021 Oct; 80(10):1330-1338. PubMed ID: 34127481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-1 Inhibitors and Vaccination Including COVID-19 in Inflammatory Rheumatic Diseases: A Nonsystematic Review.
    Atagündüz P; Keser G; Soy M
    Front Immunol; 2021; 12():734279. PubMed ID: 35154066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.
    Furer V; Rondaan C; Heijstek MW; Agmon-Levin N; van Assen S; Bijl M; Breedveld FC; D'Amelio R; Dougados M; Kapetanovic MC; van Laar JM; de Thurah A; Landewé RB; Molto A; Müller-Ladner U; Schreiber K; Smolar L; Walker J; Warnatz K; Wulffraat NM; Elkayam O
    Ann Rheum Dis; 2020 Jan; 79(1):39-52. PubMed ID: 31413005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A practical approach to vaccination of patients with autoimmune inflammatory rheumatic diseases in Australia.
    Wong PKK; Bagga H; Barrett C; Hanrahan P; Johnson D; Katrib A; Leder K; Marabani M; Pentony P; Riordan J; White R; Young L
    Intern Med J; 2017 May; 47(5):491-500. PubMed ID: 28101910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases.
    Furer V; Rondaan C; Agmon-Levin N; van Assen S; Bijl M; Kapetanovic MC; de Thurah A; Mueller-Ladner U; Paran D; Schreiber K; Warnatz K; Wulffraat NM; Elkayam O
    RMD Open; 2021 Feb; 7(1):. PubMed ID: 33627440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series.
    Furer V; Zisman D; Kibari A; Rimar D; Paran Y; Elkayam O
    Rheumatology (Oxford); 2021 Oct; 60(SI):SI90-SI95. PubMed ID: 33848321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases.
    Bühler S; Eperon G; Ribi C; Kyburz D; van Gompel F; Visser LG; Siegrist CA; Hatz C
    Swiss Med Wkly; 2015; 145():w14159. PubMed ID: 26218860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of vaccination in rheumatic disease.
    Wong PKK; Hanrahan P
    Best Pract Res Clin Rheumatol; 2018 Dec; 32(6):720-734. PubMed ID: 31427051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of the mRNA-1273 and ChAdOx1 nCoV-19 vaccines in Asian patients with autoimmune rheumatic diseases under biologic and/or conventional immunosuppressant treatments.
    Liao HT; Tung HY; Chou CT; Tsai HC; Yen YN; Tsai CY
    Scand J Rheumatol; 2022 Nov; 51(6):500-505. PubMed ID: 35638589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations.
    Rondaan C; Furer V; Heijstek MW; Agmon-Levin N; Bijl M; Breedveld FC; D'Amelio R; Dougados M; Kapetanovic MC; van Laar JM; Ladefoged de Thurah A; Landewé R; Molto A; Müller-Ladner U; Schreiber K; Smolar L; Walker J; Warnatz K; Wulffraat NM; van Assen S; Elkayam O
    RMD Open; 2019; 5(2):e001035. PubMed ID: 31565247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists.
    Santosa A; Xu C; Arkachaisri T; Kong KO; Lateef A; Lee TH; Leong KH; Low AHL; Sriranganathan MK; Tan TC; Teng GG; Thong BY; Fong W; Lahiri M
    Int J Rheum Dis; 2021 Jun; 24(6):746-757. PubMed ID: 33973379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cluster analysis reveals three main patterns of beliefs and intention with respect to SARS-CoV-2 vaccination in patients with autoimmune and inflammatory diseases.
    Felten R; Dubois M; Ugarte-Gil MF; Chaudier A; Kawka L; Bergier H; Costecalde C; Pijnenburg L; Fort J; Chatelus E; Sordet C; Javier RM; Gottenberg JE; Sibilia J; Fuentes-Silva YJ; Arnaud L
    Rheumatology (Oxford); 2021 Oct; 60(SI):SI68-SI76. PubMed ID: 33983432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Use of COVID-19 Vaccines in Patients with SLE.
    Tang W; Gartshteyn Y; Ricker E; Inzerillo S; Murray S; Khalili L; Askanase A
    Curr Rheumatol Rep; 2021 Nov; 23(11):79. PubMed ID: 34767100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study.
    Furer V; Eviatar T; Freund T; Peleg H; Paran D; Levartovsky D; Kaufman I; Broyde A; Elalouf O; Polachek A; Feld J; Haddad A; Gazitt T; Elias M; Higazi N; Kharouf F; Gertel S; Pel S; Nevo S; Hagin D; Zisman D; Elkayam O
    Ann Rheum Dis; 2022 Nov; 81(11):1594-1602. PubMed ID: 35868846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should we vaccinate during an active rheumatic disease?
    Bijl M; Westra J; Mancuso S; Bearzi P; Giacomelli R; Conti F
    Autoimmun Rev; 2024 Jan; 23(1):103426. PubMed ID: 37634680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.
    Spiera R; Jinich S; Jannat-Khah D
    Ann Rheum Dis; 2021 Oct; 80(10):1357-1359. PubMed ID: 33975857
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical outcomes and risk factors in patients with COVID-19 and autoimmune rheumatic diseases: insights from a major Australian hospital study.
    Ling Z; Guy S; Fong C
    Intern Med J; 2024 Oct; 54(10):1634-1643. PubMed ID: 39136111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions.
    Krasselt M; Wagner U; Nguyen P; Pietsch C; Boldt A; Baerwald C; Pierer M; Seifert O
    Rheumatology (Oxford); 2022 Jun; 61(SI2):SI180-SI188. PubMed ID: 35143648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.
    Bonelli MM; Mrak D; Perkmann T; Haslacher H; Aletaha D
    Ann Rheum Dis; 2021 Oct; 80(10):1355-1356. PubMed ID: 33958323
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 57.